文献速递白血病淋巴瘤

唐氏综合征急性淋巴细胞白血病患儿的微小残留病、长期结局与IKZF1缺失:一项匹配队列研究

Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
PubMed 文献 · Lancet Haematol · 2021-01-01

该匹配队列研究纳入2002-2018年八项试验中1-23岁唐氏综合征合并急性淋巴细胞白血病患者及匹配的非唐氏综合征对照,比较诱导后MRD水平及长期结局。结果显示两组高MRD比例相似,但唐氏综合征患者在IKZF1缺失组复发风险更高,且诱导后治疗相关死亡率显著升高。

要点

  • 唐氏综合征合并ALL患者诱导后高MRD比例与匹配对照相似(38% vs 39%)。

核心结论

  • 诱导治疗对唐氏综合征合并ALL患者与匹配的非唐氏综合征患者效果相当。
  • 唐氏综合征本身在IKZF1缺失个体中增加额外复发风险,提示胚系环境与不良体细胞畸变的交互作用。
  • 考虑固有复发风险和高治疗相关死亡风险,需要不同的治疗策略。

研究设计与样本

  • 匹配队列研究,纳入2002-2018年八项试验中1-23岁唐氏综合征合并ALL患者及匹配的非唐氏综合征ALL对照。
  • 共251例唐氏综合征合并ALL患者,其中136例符合分析条件,按1:3匹配407例非唐氏综合征对照。
  • 匹配因素包括临床危险因素和遗传学(含IKZF1缺失),MRD分析队列和长期结局队列分别匹配。

主要发现

  • 诱导结束时高MRD(≥0·0001)比例在唐氏综合征组为52/136(38%),匹配对照组为157/403(39%);OR 0·97(95% CI 0·64-1·46),p=0·88。
  • IKZF1缺失组中,唐氏综合征患者5年复发率37·1%(17·1-57·2),匹配对照13·2%(6·1-23·1);HRcs 4·3(1·6-11·0),p=0·0028。
  • IKZF1野生型组中,唐氏综合征患者5年复发率5·8%(2·1-12·2),匹配对照8·1%(5·1-12·0);HRcs 1·0(0·5-2·1),p=0·99。
  • 诱导期死亡:唐氏综合征组15/251(6%),非唐氏综合征组69/8426(0·8%)。
  • 诱导后治疗相关死亡率:唐氏综合征组5年12·2%(7·0-18·9),匹配对照2·7%(1·3-4·9);HRcs 5·0(2·3-10·8),p<0·0001。

关键数值与推荐

  • 高MRD定义为绝对MRD水平≥0·0001,低MRD定义为<0·0001。
  • 唐氏综合征合并ALL患者诱导后高MRD比例与匹配对照相似(38% vs 39%)。
  • IKZF1缺失的唐氏综合征患者5年复发风险显著高于匹配对照(37·1% vs 13·2%)。
  • 唐氏综合征患者诱导后5年治疗相关死亡率显著高于匹配对照(12·2% vs 2·7%)。

临床怎么用

  • 唐氏综合征合并ALL患者诱导治疗疗效与非唐氏综合征患者相当,不应因唐氏综合征而削弱诱导治疗。
  • 对IKZF1缺失的唐氏综合征患者应警惕更高复发风险,需强化监测或考虑不同治疗策略。
  • 唐氏综合征患者治疗相关死亡风险高,需加强支持治疗和并发症管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with Down syndrome and acute lymphocytic leukaemia are at an increased risk of treatment-related mortality and relapse, which is influenced by unfavourable genetic aberrations (eg, IKZF1 deletion). We aimed to investigate the potential underlying effect of Down syndrome versus the effects of adverse cancer genetics on clinical outcome. METHOD: Patients (aged 1-23 years) with Down syndrome and acute lymphocytic leukaemia and matched non-Down syndrome patients with acute lymphocytic leukaemia (matched controls) from eight trials (DCOG ALL10 and ALL11, ANZCHOG ALL8, AIEOP-BFM ALL2009, UKALL2003, NOPHO ALL2008, CoALL 07-03, and CoALL 08-09) done between 2002 and 2018 across various countries (the Netherlands, the UK, Australia, Denmark, Finland, Iceland, Norway, Sweden, and Germany) were included. Participants were matched (1:3) for clinical risk factors and genetics, including IKZF1 deletion. The primary endpoint was the comparison of MRD levels (absolute MRD levels were categorised into two groups, low [<0·0001] and high [≥0·0001]) between patients with Down syndrome and acute lymphocytic leukaemia and matched controls, and the secondary outcomes were comparison of long-term outcomes (event-free survival, overall survival, relapse, and treatment-related mortality [TRM]) between patients with Down syndrome and acute lymphocytic leukaemia and matched controls. Two matched cohorts were formed: for MRD analyses and for long-term outcome analyses. For both cohorts, matching was based on induction regimen; for the long-term outcome cohort, matching also included MRD-guided treatment group. We used mixed-effect models, Cox models, and competing risk for statistical analyses. FINDINGS: Of 251 children and adolescents with Down syndrome and acute lymphocytic leukaemia, 136 were eligible for analyses and matched to 407 (of 8426) non-Down syndrome patients with acute lymphocytic leukaemia (matched controls). 113 patients with Down syndrome and acute lymphocytic leukaemia were excluded from matching in accordance with predefined rules, no match was available for two patients with Down syndrome and acute lymphocytic leukaemia. The proportion of patients with high MRD at the end of induction treatment was similar for patients with Down syndrome and acute lymphocytic leukaemia (52 [38%] of 136) and matched controls (157 [39%] of 403; OR 0·97 [95% CI 0·64-1·46]; p=0·88). Patients with Down syndrome and acute lymphocytic leukaemia had a higher relapse risk than did matched controls in the IKZF1 deleted group (relapse at 5 years 37·1% [17·1-57·2] vs 13·2% [6·1-23·1]; cause-specific hazard ratio [HRcs] 4·3 [1·6-11·0]; p=0·0028), but not in the IKZF1 wild-type group (relapse at 5 years 5·8% [2·1-12·2] vs 8·1% [5·1-12·0]; HRcs 1·0 [0·5-2·1]; p=0·99). In addition to increased induction deaths (15 [6%] of 251 vs 69 [0·8%] of 8426), Down syndrome and acute lymphocytic leukaemia was associated with a higher risk of post-induction TRM compared with matched controls (TRM at 5 years 12·2% [7·0-18·9] vs 2·7% [1·3-4·9]; HRcs 5·0 [2·3-10·8]; p<0·0001). INTERPRETATION: Induction treatment is equivalently effective for patients with Down syndrome and acute lymphocytic leukaemia and for matched patients without Down syndrome. Down syndrome itself provides an additional risk in individuals with IKZF1 deletions, suggesting an interplay between the germline environment and this poor risk somatic aberration. Different treatment strategies are warranted considering both inherent risk of relapse and high risk of TRM. FUNDING: Stichting Kinder Oncologisch Centrum Rotterdam and the Princess Máxima Center Foundation, NHMRC Australia, The Cancer Council NSW, Tour de Cure, Blood Cancer UK, UK Medical Research Council, Children with Cancer, Swedish Society for Pediatric Cancer, Swedish Childhood Cancer Fund, Danish Cancer Society and the Danish Childhood Cancer Foundation.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Michels N, Boer JM, Enshaei A, et al. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study. Lancet Haematol. 2021. PMID: 34560013. doi:10.1016/S2352-3026(21)00272-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。